

MTN-003 Study-Specific Procedures Manual

Table of Contents

Section 1. Introduction

1.1	Sources of Procedural Information.....	1-1
1.2	Investigator Responsibilities	1-1
1.3	Study Activation Process.....	1-2

Section 2. Protocol

Section 3. Documentation Requirements

3.1	Essential Documents	3-1
3.2	Participant Case History Documentation	3-2
	3.2.1 Case History Contents.....	3-2
	3.2.2 Concept of Source Data and Source Documentation	3-3
	3.2.3 Document Organization	3-5
3.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation	3-6
3.4	Record Retention Requirements.....	3-8

Section 4. Participant Accrual

4.1	Study Accrual Plan and Site-Specific Accrual Targets.....	4-1
4.2	Screening and Enrollment	4-2
	4.2.1 Definition of Screening.....	4-2
	4.2.1.1 Assessment of Acute HIV Infection Prior to Enrollment	4-7
	4.2.2 Screening Visit Locations	4-7
	4.2.3 Definition of Enrollment	4-7
	4.2.4 Screening and Enrollment Timeframe.....	4-8
	4.2.5 Enrollment Split Visits	4-9
	4.2.6 Screening and Enrollment Logs	4-9
	4.2.7 Assignment of Participant ID Numbers	4-10
	4.2.8 Screening HIV Testing.....	4-10
	4.2.9 Eligibility Screening Scenarios	4-11
	4.2.10 Random Assignment	4-11
	4.2.10.1 Overview	4-11
	4.2.10.2 Participant-Specific Procedures.....	4-17
4.3	Product Use Instructions, First Product Use, and Adherence Counseling	4-18

Section 5. Informed Consent

5.1	Overview of Informed Consent Requirements and Procedures	5-1
5.2	Informed Consent for Screening	5-3
5.3	Informed Consent for Enrollment	5-3
	5.3.1 Informed Consent Process for Participants who Resume Study Participation After Voluntary Withdrawal.....	5-4

5.3.2	Informed Consent Support Materials	5-4
5.3.3	Comprehension Assessment.....	5-8
5.4	Informed Consent for Specimen Storage and Possible Future Research Testing	5-10
5.5	Documenting the Informed Consent Process	5-10
5.6	Ongoing Assessment of Participant Comprehension	5-11
5.6.1	Frequency of Ongoing Assessment.....	5-11
5.6.2	Administering the Ongoing Assessment.....	5-12
5.6.3	Responding to Participant Information Needs After Administering the Ongoing Assessment.....	5-12
5.6.4	Documenting the Ongoing Assessment	5-12

Section 6. Participant Follow-up

6.1	Study Follow-up Plan and Participant Retention Targets	6-1
6.2	Types of Follow-up Visits.....	6-2
6.3	Follow-up Visit Scheduling.....	6-2
6.3.1	Target Visit Dates.....	6-2
6.3.2	Visit Windows.....	6-2
6.3.3	Visits Conducted Over Multiple Days: “Split Visits”	6-4
6.3.3.1	Study Product Considerations During Split Visits	6-5
6.3.4	Missed Visits	6-6
6.4	Follow-up Visit Locations.....	6-6
6.5	Follow-up Visit Procedures.....	6-10
6.6	HIV Testing During Follow-Up	6-13
6.7	Study Product Return, Re-Supply, and Re-Issue During Follow-up.....	6-15
6.7.1	Study Product Return	6-16
6.7.2	Study Product Re-Supply	6-19
6.7.3	Study Product Re-Issue	6-23
6.8	Modified Follow-up Procedures for Participants Who Become Pregnant	6-25
6.9	Modified Follow-up Procedures for Participants Infected with Hepatitis B	6-26
6.10	Modified Follow-up Procedures for Participants Who Become Infected with HIV	6-27
6.11	Participant Transfers.....	6-32
6.12	Early Terminations Prior to the Expected PUEV	6-33
6.12.1	Early Terminations After the PUEV	6-33
6.13	Resumption of Study Participation After Voluntary Withdrawal	6-34

Section 7. Visit Checklists

7.1	Use of Visit Checklists.....	7-1
7.2	Sequence of Procedures.....	7-2

Section 8. Participant Retention

8.1	Retention Definitions	8-1
8.2	Retention Requirements	8-2
8.3	Retention SOPs.....	8-3
8.4	Obtaining and Updating Locator Information.....	8-3
8.5	Retention Tips	8-4

Section 9. Study Product Considerations for Non-Pharmacy Staff

9.1	Responsibilities and Obligations with Regard to Blinding	9-1
9.2	Study Product Identification and Terminology	9-3
9.3	Study Product Regimens	9-3
9.4	Instructions for Inserting Study Gel and Taking Study Tablets	9-4
9.5	Dispensing Study Products During On-Site Visits.....	9-5
	9.5.1 Dispensing from the Pharmacy Directly to Participants	9-6
	9.5.2 Dispensing from the Pharmacy to Clinic Staff.....	9-6
	9.5.3 Dispensing from the Pharmacy to Runners for Transfer to Clinic Staff	9-7
9.6	Dispensing Study Products and Collecting Unused Study Products at In-Home Follow-Up Visits.....	9-7
	9.6.1 Delivering Study Products During an In-Home Visit for a Participant Who Left the Clinic Early.....	9-9
9.7	Dispensing More Than a 60-Day Supply of Study Product	9-10
9.8	Study Product Returns.....	9-11
9.9	Study Product Retrieval.....	9-12

Section 10. Clinical Considerations

10.1	Baseline Medical/Menstrual History and Ascertainment of Concomitant Medications	10-1
	10.1.1 Baseline Medical/Menstrual History	10-1
	10.1.2 Initial Ascertainment of Concomitant Medications.....	10-4
	10.1.3 Pre-Existing Conditions.....	10-5
10.2	Interval Medical/Menstrual History and Updating of Concomitant Medications	10-6
	10.2.1 Interval Medical/Menstrual History	10-6
	10.2.2 Updating Concomitant Medications Information.....	10-7
10.3	Hepatitis B Vaccination.....	10-7
10.4	Physical Exams.....	10-8
	10.4.1 Weight	10-8
	10.4.2 Height	10-9
	10.4.3 Blood Pressure.....	10-10
10.5	Pelvic Exams	10-11
	10.5.1 Overview	10-11
	10.5.2 Detailed Procedural Instructions	10-12
	10.5.3 Documentation of Findings	10-14
10.6	Genital Bleeding Assessment	10-18
	10.6.1 Genital Bleeding Assessment for Pregnant Participants	10-18
	10.6.2 Participant Reports of Genital Bleeding.....	10-20
	10.6.3 Clinician Assessment of Genital Bleeding.....	10-20
	10.6.4 Documentation of Genital Bleeding.....	10-24
10.7	STI/RTI Management.....	10-27
	10.7.1 STI/RTI Treatment	10-27
	10.7.2 Screening and Enrollment Considerations	10-30
	10.7.3 Adverse Event Reporting Considerations	10-31
10.8	Pap Smear Management.....	10-32
10.9	Urinary Tract Infections	10-33
10.10	Contraception Considerations	10-34
10.11	Pregnancy and Breastfeeding Considerations	10-35

10.12	Care and Support for Seroconverters	10-36
10.13	Calculating Creatinine Clearance Rates	10-36
10.14	Management of Laboratory Test Results	10-37
10.15	Clinical and Product Use Management	10-37

Section 11. Adverse Event Reporting and Safety Monitoring

11.1	Definitions and General Reporting Guidance	11-1
11.1.1	Adverse Event (AE)	11-1
11.1.2	Reportable Adverse Events	11-2
11.1.3	Serious Adverse Events (SAEs)/ Expedited Adverse Events (EAEs).....	11-7
11.1.4	Reporting EAEs.....	11-8
11.2	Adverse Event Terminology	11-10
11.3	Adverse Event Severity	11-13
11.4	Adverse Event Relationship to Study Product	11-18
11.5	Adverse Event Outcomes and Follow-Up Information.....	11-19
11.6	Reporting Recurrent Adverse Events	11-22
11.7	Social Harms	11-23
11.8	MTN-003 Safety Monitoring, Review, and Oversight.....	11-24
11.9	Safety Distributions from DAIDS	11-25

Section 12. Counseling Considerations

12.1	HIV Counseling.....	12-1
12.1.1	Risk Reduction Counseling	12-4
12.1.2	HIV Sexual Risk and Risk Reduction	12-5
12.2	Contraception Counseling	12-7
12.3	Study Product Adherence Counseling — Enrollment.....	12-8
12.3.1	Product Use Instructions	12-8
12.3.2	First Product Use.....	12-9
12.3.3	Study Product Adherence Counseling - Enrollment	12-10
12.4	Study Product Adherence Counseling — Follow-up	12-12
12.5	Product Use Instructions — Follow-up.....	12-12

Section 13. Laboratory Considerations

13.1	Overview and General Guidance.....	13-1
13.2	Specimen Labeling	13-2
13.3	Procedures for Specimens That Cannot be Evaluated.....	13-2
13.4	Use of LDMS	13-2
13.5	Urine Testing.....	13-4
13.5.1	Specimen Collection.....	13-4
13.5.2	Pregnancy Testing	13-4
13.5.3	Dipstick Urinalysis.....	13-5
13.5.4	Chlamydia and Gonorrhea Testing.....	13-5
13.6	Blood Testing	13-6
13.6.1	Specimen Collection and Initial Processing	13-6
13.6.2	HIV Testing.....	13-6
13.6.3	Syphilis Testing.....	13-8
13.6.4	Hepatitis B Surface Antigen and Surface Antibody.....	13-8

13.6.5	Hematology Testing	13-8
13.6.6	Serum Chemistries	13-9
13.6.7	Plasma Archive	13-9
13.6.8	CD4+ T Cell Count	13-10
13.6.9	HIV RNA PCR.....	13-10
13.6.10	HSV-1 and HSV-2 Testing.....	13-11
13.6.11	Peripheral Blood Mononuclear Cells (PBMC) for Drug Levels	13-11
13.7	Testing of Vaginal and Cervical Specimens	13-12
13.7.1	Vaginal pH	13-12
13.7.2	Wet Mount for Candidiasis	13-13
13.7.3	Rapid Test for Bacterial Vaginosis (BV)	13-13
13.7.4	Rapid Test for Trichomoniasis.....	13-13
13.7.5	Vaginal Gram Stain	13-14
13.7.6	Papanicolaou (Pap) Test.....	13-15
13.7.7	Vaginal Swabs for Biomarker Analysis	13-15
13.7.8	Endocervical Swabs for Biomarker Analysis.....	13-15

Section 14. Data Collection

14.1	DataFax Overview.....	14-1
14.2	DataFax Form Completion.....	14-2
14.2.1	General Guidelines.....	14-2
14.2.2	How to Mark Response Boxes	14-3
14.2.3	How to Record Numbers.....	14-3
14.2.4	How to Record Dates	14-4
14.2.5	How to Record Time	14-5
14.2.6	Data Corrections and Additions	14-6
14.2.7	How to Handle Missing and Unknown Data.....	14-7
14.3	MTN-003 Study-Specific Data Collection Information	14-7
14.3.1	Participant ID numbers (PTIDs).....	14-8
14.3.2	Study Visit Timing.....	14-8
14.3.3	Visit Codes and Page Numbers.....	14-13
14.3.4	Staff Initials/Date	14-16
14.3.5	Case Report Form Completion Schedule	14-16
14.3.6	Site Review of DataFax Forms	14-22
14.3.7	Faxing DataFax Forms	14-22
14.3.8	Non-DataFax Forms	14-23
14.4	Form Supply and Storage	14-23
14.4.1	Form and Specimen Label Supply	14-23
14.4.2	Form Storage	14-23
14.5	Completing Interviewer-administered Forms.....	14-24
14.6	Form Completion Instructions.....	14-27
14.7	Case Report Forms	14-30

Section 15. Data Communiqués

Section 16. ACASI Users Manual

Section 17. Study Reporting Plan

17.1	Purpose of Reporting Plan.....	17-1
------	--------------------------------	------

17.2	Study Reports	17-1
17.2.1	Data Quality Control (QC) Report	17-3
17.2.2	Clinical Data Quality Control (CQC) Queries	17-3
17.2.3	Unresolved Adverse Experiences Listing	17-3
17.2.4	Specimen Monitoring Report	17-3
17.2.5	Enrollment and Retention Report.....	17-3
17.2.6	Visit Adherence and Procedure Completion Report	17-4
17.2.7	Product Adherence Report	17-4
17.2.8	Site Data Management Quality Report	17-4
17.2.9	Safety (PSRT) Reports	17-4
17.2.10	Study Monitoring Committee (SMC) Report.....	17-4
17.2.11	Data Safety Monitoring Board (DSMB) Report	17-5
17.2.12	Network Lab Assay Results Report	17-5

Section 18. Bone Mineral Density Substudy

18.1	Introduction	18-2
18.2	Protocol	18-2
18.3	Documentation Requirements	18-2
18.3.1	Essential Documents	18-2
18.3.2	Participant Case History Documentation	18-2
18.3.3	Study Product Accountability, Chain of Custody, Dispensing Documentation	18-3
18.3.4	Record Retention Requirements.....	18-3
18.4	Participant Accrual	18-3
18.4.1	Study Accrual Plan and Site-Specific Accrual Targets	18-3
18.4.2	Assignment of Participant ID Numbers	18-4
18.4.3	Screening: Definition and Procedures	18-4
18.4.4	Definition of Enrollment	18-6
18.4.5	Screening and Enrollment Timeframe.....	18-6
18.4.6	Screening and Enrollment Logs	18-6
18.5	Informed Consent.....	18-7
18.6	Participant Follow-up	18-7
18.6.1	Follow-up Visit Scheduling.....	18-7
18.6.2	Follow-up Visit Procedures.....	18-10
18.6.3	Modified Follow-up Procedures for Participants Who Temporarily Hold or Permanently Discontinue Study Product.....	18-10
18.7	Visit Checklists.....	18-10
18.8	Participant Retention	18-10
18.9	Study Product Considerations	18-10
18.10	DXA Scanning Procedures and Other Clinical Considerations	18-10
18.11	Adverse Event Reporting and Safety Monitoring	18-13
18.12	Counseling Considerations.....	18-14
18.13	Laboratory Considerations	18-16
18.13.1	Urine Collection and Storage	18-16
18.13.2	Blood Collection and Serum Storage	18-16
18.13.3	Guide to Logging in MTN-003B Specimens in LDMS	18-16
18.14	Data Collection.....	18-16
18.14.1	PTIDs	18-16
18.14.2	Study Visit Timing.....	18-17
18.14.3	Visit Codes	18-17

18.14.4 Case Report Form Completion Schedule	18-20
18.14.5 Form and Specimen Label Supply	18-20
18.14.6 Form Storage	18-21
18.14.7 How to Complete Interviewer-Administered Forms	18-21
18.14.8 Form Completion Instructions	18-21
18.14.9 Case Report Forms	18-21
18.15 Data Communiqués	18-21

Section 19: Household and Community Factors Associated with VOICE Product Adherence Substudy (VOICE-C)

19.1 Introduction	19-2
19.2 Protocol	19-3
19.3 Documentation Requirements	19-3
19.3.1 Essential Documents	19-3
19.3.2 Participant File Documentation	19-4
19.3.2.1 Participant File Contents	19-4
19.3.2.2 Concept of Source Data and Source Documentation	19-5
19.3.2.3 Document Organization.....	19-6
19.3.3 Record Retention Requirements	19-8
19.4 Participant Accrual	19-8
19.4.1 Study Accrual Plan and Site-Specific Accrual Targets	19-8
19.4.2 Assignment of Participant ID Numbers.....	19-11
19.4.3 Screening Definition and Eligibility Criteria.....	19-11
19.4.4 Definition of Enrollment	19-16
19.4.5 Screening and Enrollment Timeframe.....	19-17
19.4.6 Screening and Enrollment Logs	19-17
19.4.7 Weekly VOICE-C Progress Reports	19-18
19.5 Informed Consent	19-18
19.6 Visit Procedures	19-19
19.6.1 Visit Scheduling	19-19
19.6.2 Data Collection Procedures	19-21
19.6.3 Modified Procedures for Participants Who Miss Scheduled Data Collection Visits.....	19-24
19.7 Visit Checklists.....	19-24
19.8 Participant Retention	19-24
19.9 Reporting of Social Harms, Adverse Events and Adherence Issues	19-24
19.10 Counseling Considerations	19-26
19.11 Data Collection	19-26
19.11.1 PTIDs.....	19-26
19.11.2 Study Visit Timing	19-26
19.11.3 Visit Codes	19-27
19.11.4 Case Report Form Completion Schedule	19-28
19.11.5 Form Supply	19-28
19.11.6 Form Storage	19-28
19.11.7 How to Complete Interviewer Administered Forms	19-28
19.11.8 Form Completion Instructions.....	19-29
19.11.9 Case Report Forms	19-29
19.11.10 Data Flow: Quantitative Data Management	19-29
19.11.11 Data Flow: Qualitative Data Management	19-30